Blinatumomab as postremission therapy replaces consolidation and substantial parts of maintenance chemotherapy and results in stable MRD negativity in children with newly diagnosed B-lineage ALL

Blinatumomab as postremission therapy replaces consolidation and substantial parts of maintenance chemotherapy and results in stable MRD negativity in children with newly diagnosed B-lineage ALL

The bispecific T cell-binding antibody blinatumomab (CD19/CD3) is widely and successfully used for the treatment of children with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Here, we report the efficacy of a single course of blinatumomab instead of consolidation c...

Full description

Saved in:
Bibliographic Details
Main Authors: Guenter Henze, Ekaterina Mikhailova, Alexander Popov, Julia Roumiantseva, Oleg Budanov, Svetlana Lagoyko, Liudmila Zharikova, Natalia Miakova, Dmitry Litvinov, Lili Khachatryan, Alexey Pshonkin, Natalia Ponomareva, Elmira Boichenko, Svetlana Varfolomeeva, Julia Dinikina, Galina Novichkova, Alexander Karachunskiy
Format: Article
Language:English
Published: BMJ Publishing Group 2024-06-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/6/e008213.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/12/6/e008213.full

Similar Items